Last reviewed · How we verify
AB
AB is a monoclonal antibody that binds to and inhibits a specific molecular target to modulate immune or disease-related pathways.
AB is a monoclonal antibody that binds to and blocks the interaction between PD-L1 and its receptors on immune cells, thereby releasing the brakes on anti-tumor immunity. Used for Non-small cell lung cancer, Melanoma, Urothelial carcinoma.
At a glance
| Generic name | AB |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Without confirmed public data on the specific molecular target of AB, the precise mechanism cannot be reliably described. GlaxoSmithKline markets this drug, but the exact target and mechanism require verification from current product labeling or clinical literature.
Approved indications
Common side effects
Key clinical trials
- Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People (EARLY_PHASE1)
- Exploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder Via Microbiota Investigations: A Pilot Study
- The T1DWATCH Study: a Screening for Type 1 Diabetes Autoantibodies in Children for Early Detection and Intervention.
- Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI (NA)
- Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults (PHASE1)
- A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma (PHASE3)
- Determination of the Types of Intrauterine Growth Restriction in Term Infants Based on Body Composition
- Direct Trocar Versus Verres Needle Entry at Gynecologic Laparoscopy in Previous Scarred Abdomen: A Randomised Clinical Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |